Not that I know anything about their approach, but any form of analysis that does not strongly factor in the past, present and future fundamentals analysis of this company, be it chart trading based or financials/sector etc based is of no interest to me. [Only talking about an anectotal company (Neuren in this case), not the market in general.]
The reason for me, is that the fundamentals dominate. (In that regard, we are awaiting some pretty important fundamentals information re the PMS/FDA P3 related outlook. Hopefully the wait is not too much longer, as Jon did indicate during the FDA meeting webinar, that he expected a reasonably quick finalisation of the end points - that was a while back now).
NEU Price at posting:
$13.28 Sentiment: Hold Disclosure: Held
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)